Vicore Pharma

New Phase IIa data indicates that Vicore Pharma’s C21 has the potential to transform the treatment of idiopathic pulmonary fibrosis (IPF) and restore lung function. In data from the AIR trial, C21 has demonstrated long-term efficacy. At 36 weeks, the average forced vital capacity (FVC) had increased to +350ml over baseline, which is +530ml over […]

Vicore Pharma, a Swedish clinical-stage pharmaceutical company unlocking the potential of angiotensin II type 2 receptor agonists (ATRAGs), has dosed its first patient with C21 in a clinical study of endothelial dysfunction.    Vicore Pharma states that results from the trial are expected in Q4, 2023.  The study   Vicore is conducting a randomised, double-blind, placebo-controlled, cross-over […]